Chemical Property of Pomalidomide
Chemical Property:
- Vapor Pressure:1.41E-13mmHg at 25°C
- Melting Point:318.5 - 320.5°
- Refractive Index:1.691
- Boiling Point:582.933 °C at 760 mmHg
- PKA:10.75±0.40(Predicted)
- Flash Point:306.347 °C
- PSA：109.57000
- Density:1.57 g/cm3
- LogP:0.51790
- Storage Temp.:2-8°C
- Solubility.:DMSO: ≥14mg/mL
- XLogP3:0.2
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:1
- Exact Mass:273.07495584
- Heavy Atom Count:20
- Complexity:504
- Purity/Quality:
-
99% *data from raw suppliers
Pomalidomide *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Antineoplastic Agents
- Canonical SMILES:C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
- Recent ClinicalTrials:A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Recent EU Clinical Trials:A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma
- Recent NIPH Clinical Trials:Multi-center, open-label, Phase 1b study in patients with relapsed/refractory multiple myeloma (RRMM)
-
Description
Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. In February 2013, the US FDA approved pomalidomide (also known as CC4047) for the treatment of multiple myeloma (MM) in patients with disease progression after receiving other cancer therapeutics. Pomalidomide is a 4-amino analog of thalidomide with enhanced potency and an improved toxicity profile. Pomalidomide and thalidomide exert their effects by modulation of immunity, inhibition of angiogenesis, interference with the bone/tumor microenvironment, and inhibition of the cereblon protein. Pomalidomide potently inhibited in vitro proliferation in a variety of human MM cell lines, IC50～10 nM, while thalidomide showed almost no inhibition up to 100 μM. In mouse MM tumor models, 50 mg/kg daily doses of pomalidomide resulted in marked inhibition of tumor growth after 15 days of treatment and complete regression in 3–6 weeks versus thalidomide-treated controls at the same dose. Pomalidomide is prepared by condensation of 4-nitrophthalic anhydride with 3-aminopiperidine-2,6-dione followed by catalytic hydrogenation of the nitro group.
-
Uses
Pomalidomide is a thalidomide derivative, a potent inhibitor of TNF-α production. It is an antiinflammatory and antitumor agent used in the treatment of multiple myeloma. Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease. Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM
-
Clinical Use
Treatment of multiple myeloma
-
Drug interactions
Potentially hazardous interactions with other drugs
Antidepressants: concentration increased by
fluvoxamine.
